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and European countries. Methods: Comparison of miligram based prices analy-
sis between European countries done by Intelligent Health System(IHS) was used. 
The analysis of IHS included Germany, France, United Kingdom(UK), Spain and 
Italy(EU5). Comparison was done with taken row data of analysis EU5 and Turkey 
average milligram retail prices of Ceftriaxone, Clopidogrel, Esomeprazole, Fentanyl, 
Lamotrigine, Levofloxacin, Metformin, Venlafaxine, Letrozole and Olanzapine 
molecules. Results: It has been reported that compared 10 molecules highest 
average miligram based prices of Esomeprazole(0,043 € ), Levofloxacin(0,058 € ) and 
Clopidogrel(0,0083 € ) molecules belong to Turkey, Lamotrigine(0,01 € ) belongs to 
Germany. The highest average miligram based prices of other 6 molecules belong 
to UK with following; Ceftriaxone(0,0196 € ), Fentanyl(0,186 € ), Letrozole(1,24 € ), 
Metformine(0,00013 € ), Venlafaxine(0,0074 € ), Olanzapine(0,261 € ). ConClusions: 
It has known that because of UK used free pricing mechanism on drugs, prices of 
drugs are higher than other compared countries. This sitiuation established on the 
anaylsis. But despite of Turkish Government policy decisions; it is important indicia-
tion that 3 drugs represents highest prices out 10 drugs. Reference pricing system 
applied based on box price. Better control mechanism may achievable if miligram 
based pricing apply in Turkey. On the other hand because of the study only consist 
retail sales prices the evaluation should be done from point of reimbursement 
prices on future studies.
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objeCtives: The expiration of biotech drugs patent has led to the creation of drugs 
copies of originator products, defined ‘biosimilars’. No European country allows 
automatic substitution between the originator and the biosimilar. In Italy, due to 
the lack of a national legislation, some Regions have issued directives to encour-
age the use of biosimilars, recognizing a potential saving of resources. Campania 
Region was the first region to legislate on the matter, (decree no. 15 of 11.30.2009) 
supporting the prescription of biosimilars to the naive patient. The aim of our 
study is to describe trends in biosimilars consumption in Campania region and 
evaluate how biosimilar products are replacing the originators in the respective 
markets. Methods: IMS Health regional database was used to analyze biosimi-
lar drugs consumption patterns (erythropoietins, G-CSF, somatropin) in the years 
2009- 2012. Information was retrieved about different distribution channels (retail, 
direct distribution, hospital). Consumptions are expressed in Counting Units (CU) 
and trends have been calculated using Compound Average Grow Rate (CAGR). The 
study especially focused on consumption trends of erythropoietin (ATC B03XA) in 
the years 2009-2012. Results: In 2012 the penetration rate of biosimilars was 40.1% 
(evaluated as the biosimilars share of the total erythropoietins, G-CSF, somatropin 
market). These values are double than those at national level, that are estimated to 
be 19.7% of consumption. Focus on erythropoietin trends showed a strong increase 
in biosimilars consumption (451 CU in 2009 vs 140,327 CU in 2012) after the introduc-
tion of regional measures to promote the prescription of biosimilars to the naive 
patient. In 2012, biosimilar erythropoietins and reference drugs show similar market 
shares (37.0% and 33.7% of the total erythropietins market respectively) showing 
a high substitution effect. ConClusions: Our analysis outlines the significant 
effects of regional measures on market penetration rates of biosimilars.
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objeCtives: Estimation of the direct and indirect savings generated by parallel 
importing (PI) of pharmaceutical products in public pharmacies in Poland, and esti-
mation of the savings for the payer in the case of reimbursed drugs. Methods: IMS 
Health Poland National Sales Data (2005-2012) and data from respective reimburse-
ment lists were used for all calculations. Direct savings were estimated considering 
all PI products sold in public pharmacies(433 products, 1550 SKUs). To avoid overes-
timation, only 18 products that passed restrictive criteria were used for calculations 
of indirect savings. Twenty-seven reimbursed products were used for the payer 
savings calculations. Direct savings were calculated as a difference between PI and 
reference product prices multiplied by the number of packs of PI product. Indirect 
savings were calculated as a difference between the reference product price and 
the theoretical reference product price (i.e. prices in a hypothetical situation where 
there is no price pressure caused by PI – calculated using linear regression). Indirect 
savings considered only those products which met the criteria of the reference 
product’s price decrease of at least 5% within 3 months prior to, or after, the appear-
ance of the PI product. Results: Study revealed that the savings generated by the 
PI of pharmaceuticals in Poland between 2005-2012 may be estimated at the level 
of EUR 146m (direct savings EUR 46m and indirect savings EUR 100m). Savings for 
the payer calculated for reimbursed products between 2008-2012 reached the level 
of EUR 0.06m. ConClusions: This is the first study estimating direct and indirect 
savings coming from PI phenomena covering all years since PI was reinforced by 
Poland’s accession to the EU. It has been found very interesting that indirect sav-
ings tend to be substantially higher that direct ones. This indicates that high price 
pressure is created by PI, and affects the prices of reference products.
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assessment outcomes, 2) analyze correlations between additional benefit, budget 
impact and negotiated rebate. Methods: To achieve objective 1, assessments by 
the GBA and the IQWiG (Institute for Quality and Efficiency in Healthcare) (source: 
GBA website) were scanned for key trends. To achieve objective 2, list and post-
negotiation prices were extracted from the Lauer-Taxe (German price database). 
For the 10 agents that had so far completed price negotiations, these were mapped 
against additional benefit and the budget impact (annual therapy costs as stated 
in GBA assessment). Results: The results linked to objective 1, which were more 
qualitative in nature, allowed for the extraction of 5 key learnings for manufacturers 
to keep in mind. The results associated with objective 2 showed no link between 
additional benefits granted and negotiated rebate but did reveal price impacting 
parameters apart from budget impact. ConClusions: Concerning objective 1, the 
ways in which manufacturers can attempt to optimize benefit outcomes include: 1. 
Focus on comparator choice, 2. Focus on hard endpoints, 3. Make patient segmenta-
tion more solid, 4. Expect independent action of GBA and IQWiG and 5. Accept that 
there is no methodological standard for the definition of an additional benefit. 
Regarding objective 2, we concluded that budget impact, influenced primarily by 
target population size, annual therapy costs and drug price, is an – if not the most 
important driver in the negotiation.
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objeCtives: To assess how drug innovation is rewarded and how it is impacted 
by cost-containment policies. Methods: Manufacturer prices per unit of pack-
age and strengths were compared and assessed in a basket of 97 innovative drugs 
approved by the European Medicines Agency (EMA) since 2000. The products were 
still patent protected, and available in each of the top 5 European pharmaceutical 
markets. Results: Prices of innovative drugs in Germany were still the highest and 
had a benchmark price index of 100. In France, when drugs were deemed innova-
tive, premium prices were granted – resulting in a price index of 94 – but signifi-
cantly decreased over time. While prices at launch in Italy, Spain and the UK were 
commonly lower – with price indexes of 89, 88 and 86 respectively - they tended 
to remain constant over time. ConClusions: Despite the fact that governments 
in developed markets are attempting to lower prices, differences still exist across 
the largest markets, enabling pharmaceutical companies to implement differential 
and protective pricing strategies. In Germany, time to market is comparatively fast 
and premium prices at launch have been granted. In future, the AMNOG reform 
will complicate this picture, although pricing premiums have still been achieved 
for drugs deemed innovative that have gone through the full AMNOG process. In 
France, although prices are relatively high at launch, they drop at time of renewal 
and innovation is granted to a limited number of drugs. Prices have been compara-
tively low at launch but remain constant in Italy and Spain, reflecting the fact that 
price cuts in those countries have often been directed towards generics, although 
these are still considered high-risk markets. In the UK, it remains to be seen how 
the value-based pricing reform will impact prices.
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objeCtives: To describe availability of orphan drugs in France, UK and Germany and 
to compare agencies’ assessments and prices. Methods: All the products designated 
as orphan drugs by the European Commission and commercialized at least in one of 
the three countries were included in the study. Comparison of prices is made per dos-
age and is based on prices per standard unit, using IMS MIDAS database. Comparison 
of assessments is based on Transparency Committee opinions, NICE guidances and 
IQWIG benefit assessments. Results: Sixty-two products (103 dosages/forms) were 
included in this study; 47 (76%; 84 dosages/forms) are commercialized in the 3 coun-
tries, 8 (13%) products in only 2 countries (6 both in Germany and UK and 2 both in 
Germany and France) and 7 (11%) only in 1 country (6 in Germany only and 1 in France 
only). Among the 84 products/dosage/forms available in the three countries, most of 
them are available at hospital (respectively 68, 70 and 77 in Germany, France and UK) 
but those available through retail pharmacists are much numerous in Germany (72 of 
them) than in France (29) or UK (30). German and UK manufacturer March 2013 retail 
prices more often higher than French one, despite the fact that among the 49 orphan 
drugs commercialized in France, 31 are innovative products (ASMR rate I to III). For 
instance, French assessment of pirfenidone was less favorable than the Germans’one, 
and German price is thus +65.2% higher than French price. French and UK HTA assess-
ments for azacitidine were both positive and led to similar prices. ConClusions: 
Most orphan drugs are available in the three studied countries but accessibility to 
them seems to be different and depends on HTA results.
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objeCtives: The reference pricing system is used for setting drug prices in Turkey 
since 2006. There are 5 reference countries following; Spain, Italy, Germany, France 
and Greece. Except those countries, manufactured or imported countries may be 
used as reference countries. Reference prices are reviewed time by time and may 
be subject to certain alterations, but evaluation of box prices may be different if 
evaluation made based on milligram. The aim of this study is to evaluate differ-
ences of average milligram sales prices of some generic medicines between Turkey 
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The margin index was 21% in 2009 and 20% in 2010. Since all drugs were Rx 
(margin was set up to 12%, VAT was fixed to 8%), this was completely expected. At 
the end of 2010, two medicines: levonorgestrel (1,5mg) and orlistat (60mg), were 
authorised as OTC medicines (free pricing, margin:25%, VAT:18%). ConClusions: 
“Lifestyle-medicines” are difficult to define. Market success depends on prod-
uct characteristics, effectiveness, tolerability, convenient drug-delivery format, 
simple dosing regimen, good safety profile, first-to-market position, premium 
prices, sustained media attention, Rx-OTC switch potential and reimbursement 
potential. Although more new “lifestyle-medicines” will be authorised in Serbia, 
market share is expected to decrease because of low purchasing power and low 
reimbursement potential.
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objeCtives: Different external price referencing (EPR) configurations are applied 
by countries worldwide. Depending on how EPR schemes are implemented, 
they may have varying effects on short- and long-run prices, market dynam-
ics, key stakeholders, and other relevant endpoints. This research evaluated 
the merits and demerits of EPR from an efficiency, equity, and quality perspec-
tive. Methods: A theoretical and empirical analysis of the effectiveness of 
EPR was conducted, based on a systematic review of the literature and stake-
holder interviews. As EPR has been most common in Europe, the study focused 
on this region. Results: The systematic review identified 100 relevant articles. 
The articles were categorised according to study characteristics and four major 
themes were identified; these findings were confirmed by the interviewees. The 
evidence suggests that EPR schemes often generate disproportionate price lev-
els in relation to national abilities to pay; this is likely due to the reliance on 
foreign list prices which do not reflect negotiated discounts. If manufacturers 
apply launch strategies to exert upward pressure on prices (e.g. launch delays or 
product withdrawals), it may also limit patient access to life-saving medicines. 
In addition, the bureaucratic complexity of many EPR schemes may undermine 
the objectives of EPR use (i.e. cost containment and macroeconomic efficiency). 
Finally, widespread EPR application may stifle pharmaceutical and biomedical 
innovation. ConClusions: A national pricing policy should provide an effec-
tive, predictable, transparent, and stable pricing environment for pharmaceutical 
products. It should internalise national priorities for health and industrial policy, 
including cost containment, employment, innovation, and trade promotion. EPR 
is associated with important short- and long-term issues. If EPR is going to con-
tinue to be applied by EU Member States and other countries, then it is necessary 
to establish guiding principles to govern EPR use across jurisdictions. Still, dif-
ferential pricing and risk-sharing agreements may represent more sustainable 
policy options.
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objeCtives: Reformulating existing drugs can improve patient convenience, com-
pliance and create new uses for the product. However, reformulations cost millions 
of Euros - a risky investment without guaranteed exclusivity or returns. This study 
assessed whether markets reward incremental value creation through reformu-
lation by comparing sales performance close to patent expiry for reformulated 
and non-reformulated products. Methods: IMS MIDAS data was interrogated to 
identify 829 small molecule, non-generic products which had peak sales above € 5M 
and lost patent protection between 2001 and 2010 in EU-5 (France, Germany, Italy, 
Spain and UK). Ex-manufacturer sales value (€ ) 2 years after patent expiry was 
compared with sales value 4 years earlier to calculate percentage value erosion 
for each of the 829 products. A subset of 133 products which launched at least 1 
reformulation close to patent protection expiry (launch between 3 years before 
and 1 year after patent protection expiry) were analysed to assess whether value 
erosion varied across countries or therapy areas. Results: Mean ex-manufacturer 
sales value erosion of reformulated products (24%) was significantly less than 
non-reformulated products (37%, P< 0.01). Reformulated product value erosion 
varied with country and therapy area. Germany saw highest number of reformu-
lations launched yet only reformulations launched in Italy showed significantly 
less value erosion than non-reformulated products (P< 0.01). Across therapy areas, 
reformulations were most common in nervous system, metabolism and anti-
infective categories. However, reformulated anti-infective product value erosion 
was pronounced while musculoskeletal and nervous system products experi-
enced significantly less value erosion than for non-reformulated products (both 
P< 0.05). ConClusions: Overall, reformulated products do maintain more value 
than non-reformulated products following loss of patent protection. Chronic 
disorders e.g. nervous and musculoskeletal system disorders appear to be the 
most promising areas for reformulating. Future reformulation potential is tightly 
linked to country-specific pricing and market access policy decisions to recognise 
incremental value products.
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objeCtives: To construct a number of pharmaceutical price indices for a broad set 
of countries, covering a range of regions, including countries with different levels 
objeCtives: Competition within therapeutic drug classes from “follow-on” drugs 
has been a highly controversial issue. Manufacturers launching new molecules 
in existing drug classes have often been criticized for inflating health systems’ 
expenses, but it has been argued that such drugs increase therapeutic options. 
Economic theory suggests that follow-on drugs induce price competition. We con-
tribute to this discussion by addressing the topic of pricing at market entry and 
price development in the German market with the distinct focus on competition 
within already existing drug classes. Methods: We measure determinants of 
price strategies of follow-on drugs using regression analyses, considering all new 
molecules launched in the German market in the period from 1993-2008. Prices of 
products are standardized on Defined Daily Dosages controlling for sales volumes 
based on data from the IMS Health DPM database, a census audit of pharmaceutical 
sales in Germany, and for the therapeutic quality of a new product using ratings 
by Fricke/Klaus as a proxy for innovation. Results: We identify prices correlating 
with therapeutic value at market entry. While the first two molecules engage in 
quality competition by offering more therapeutic options, price discounts below the 
market price can be observed from the third entrant on. Price discounts are even 
more distinct in development races with several drugs entering the market within 
two years and in classes with a low degree of therapeutic differentiation. Prices 
remain relatively constant over time. ConClusions: This study contributes to 
assessments of competition in pharmaceutical markets focusing on price strategies 
of new market entrants. After an initial phase of market building, further follow-on 
products induce price competition. Largely unchanged prices after 4 years may be 
interpreted as quality competition and can be attributed to prices in Germany being 
anchor point for international price referencing.
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objeCtives: Although generic drugs are considered to be therapeutically equivalent 
to their off-patent (branded) counterparts, the overall impact of generic substitu-
tion on clinical and economic outcomes has not been comprehensively evaluated. 
The goal of this study was to test whether 1) generics and branded products yield 
the same health outcomes; and 2) generic therapies save economic resources ver-
sus branded therapies for de-novo patients and patients on maintenance ther-
apy. Methods: We performed a systematic literature review in Medline, Cochrane 
Database of Systematic Reviews and Embase (2000-2012) to identify original research 
studies on clinical or economic outcomes with either independent or pre-post com-
parator groups. Data were aggregated using a standardized extraction form. For 
each included study, outcomes were categorized as favoring or opposing generic 
drug substitution. As we compared different outcomes, one publication could 
contribute to multiple outcome comparisons. Results: We included 40 studies 
that led to 121 outcome comparisons. Similar clinical effects were found in 74% 
of all studies in which patients were initiating therapy (de novo) and 64% of all 
studies involving maintenance therapy comparisons. 100% of the economic analy-
ses of de novo patients and 56% of comparisons of maintenance therapy patients 
showed lower costs associated with the use of original brand. Overall, 66% of the 
outcome comparisons reported similar clinical outcomes and 64% suggested that 
brand products lower costs compared to generic substitution. ConClusions: Our 
analyses suggested that clinical effects were mainly similar, whereas economic 
savings of brand to generic drug substitution may be overstated, particularly in 
sensitive therapeutic areas such as anti-epileptic drugs or immunosuppressives. 
More systematic research comparing clinical and cost outcomes with or without 
generic substitution is needed to inform policy on the use of generic substitu-
tion. ACKnoWledGeMents: We would like to thank Anke-Peggy Holtorf and 
Zoltán Kaló for their scientific input.
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objeCtives: To determine whether there was a difference between wholesale 
prices, utilization and market share, as well as to explain Rx-OTC switches and 
reimbursement possibilities of “lifestyle-medicines”, in 2009 and 2010, before and 
after the adoption of new Medicines Law, in Serbia. Methods: We investigated 
how many potential “lifestyle-medicines”, satisfying the previously determined 
criteria, were authorised for sale. Utilization, price changes and reimbursement 
status were monitored. Price index and margin index were calculated using the 
formula: I= QxP (index(I),quantity(Q),price(P)). To compare the differences in prices 
and utilization, non-parametric Mann-Whitney test was used. To test difference 
in market shares, T-test of proportion was used. Results: There were 21 regis-
tered “lifestyle-medicines”. Five medicines (oral contraceptives) were listed. In 
2009, there were 1,763,030 units dispensed worth 16,074,922€ . In 2010, 1,814,405 
units were dispensed while total value was 14,129,792€ . The average sales(€ ) were 
higher in 2009, which is not in line with the expected growth trend, but observed 
difference was not statistically significant. The wholesale price-index 2009/2010 
was -13%. This means that prices were 13% lower in 2010. In fact, during 2010, 
prices remained the same in national currency, which weakened against euro. 
